# Petrelintide

A weekly amylin injection pitched on tolerability. It caused less weight loss than the GLP-1 drugs in phase 2, with almost no extra dropouts.

Also called: ZP8396
Source page: https://peplogue.com/peptides/petrelintide/
Reviewed: 2026-10-12. Not medical advice.

## How it works

- Where it acts: Amylin receptors.
- What it changes: Stronger fullness signals and a slower-emptying stomach.
- What people notice: In phase 2, less weight loss than GLP-1 drugs, with few people stopping because of side effects.

## What the evidence shows

- **Weight loss in obesity**: Supported. ZUPREME-1 (493 people): up to 10.7% at 42 weeks, against 1.7% on placebo.

## Side effects and risks

- common: In the most effective dose group of the phase 2 trial, 4.8% stopped because of side effects, against 4.9% on placebo.
- unknown: Longer-term safety is not known.

Who should avoid it: Anyone outside a clinical trial.

## How it has been given in trials

Weekly injection under the skin. There is no approved dose.

## Legal status

- United States: undefined
- European Union: undefined
- Spain: undefined. Investigational. No authorised product in Spain (not in CIMA). The only lawful route is a clinical trial; Spanish trial sites not verified.
- Germany: undefined. Not authorised in Germany. Only available in clinical trials; sale outside trials is unlawful under the AMG (§ 21, § 96). German trial sites not checked.
- France: undefined. Investigational drug, not authorised in France. Only lawful route is a trial; ANSM says peptides bought outside the official circuit are illegal.
- Italy: undefined. Investigational. Not authorised in the EU or Italy; only reachable through a clinical trial. Italian trial sites not checked.
- Netherlands: undefined. Experimental. No marketing authorisation in the Netherlands or EU; only in clinical trials. Offering it as a medicine without authorisation is illegal.
- United Kingdom: undefined
- Canada: undefined
- Australia: undefined

## Questions people ask

**How much weight loss did petrelintide give?**

In ZUPREME-1 (493 people), loss reached up to 10.7% at 42 weeks, against 1.7% on placebo. That is less than the GLP-1 drugs achieved in phase 2.

**Is petrelintide easier to tolerate than GLP-1 drugs?**

It is pitched on tolerability. In the most effective dose group of the phase 2 trial, 4.8% stopped because of side effects, against 4.9% on placebo.

**Is petrelintide approved?**

No. Three phase 3 trials with about 7,000 people began in 2026, and there is no approved dose.

**Who makes petrelintide?**

Zealand Pharma and Roche develop it together.

## Sources

- Zealand Pharma: ZUPREME-1 results (5 Mar 2026): https://www.santelog.com/actualites-sante-nasdaq/zealand-pharma-announces-positive-phase-2-results-petrelintide-amylin-analog
- Zealand Pharma: half-year results 2026: https://www.inderes.dk/en/releases/zealand-pharma-announces-financial-results-for-the-first-half-of-2026